<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662841</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-18-08</org_study_id>
    <nct_id>NCT03662841</nct_id>
  </id_info>
  <brief_title>Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma</brief_title>
  <official_title>Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to study the safety and tumor response of ACE for large HCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transarterial treatment has been playing an important role in the treatment algorithm for
      patients with multifocal or large intrahepatic hepatocellular carcinoma not eligible for
      surgical resection, transplantation, or local ablative therapy. Among the patient group with
      intermediate tumor stage, in which the tumor dimension exceeds 10cm, the treatment outcome of
      conventional chemoembolization (cTACE), chemoembolization using drug eluting beads (DEB-TACE)
      and radioembolization using yttrium 90 is generally unsatisfactory. Some would consider HCC
      of size &gt;10cm a relative contraindication for cTACE because of the poor treatment outcome.
      However, there is no better alternative treatment for local control of these tumors. Ablative
      chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin has been found to be
      highly effective for local control of HCC as compared to cTACE in a case-control study. It is
      hypothesized that ACE is safe and effective for local control of large HCC of size &gt;10cm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Use of ACE for HCC of size &gt; 10cm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 to 6 months after treatment</time_frame>
    <description>the interval between the first treatment date and the date of radiological progression, including intralesional progression, extralesional progression, or extra-hepatic progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 to 6 months after treatment</time_frame>
    <description>Tumor response at 3 month and 6 month from the date of first treatment as evaluated by triphasic contrast enhanced CT according to the EASL criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>ACE for HCC of size &gt;10cm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablative chemoembolization (ACE)</intervention_name>
    <description>Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin</description>
    <arm_group_label>ACE for HCC of size &gt;10cm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signage of a written informed consent

          2. Age above 18 years

          3. HCC unsuitable for resection

          4. Child-Pugh A or B cirrhosis

          5. Eastern Cooperative Oncology Group performance score 0 or 1

          6. No previous treatment with liver resection, ablation, chemotherapy, radiotherapy or
             transarterial embolization (with or without chemotherapy),

          7. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.

          8. No extra-hepatic involvement on non-enhanced CT thorax and triphasic contrast enhanced
             CT abdomen.

          9. No invasion of portal vein or hepatic vein

         10. Massive expansive tumor morphology with measurable lesion on CT (characterized by
             well-defined spherical or globular configuration, with or without tumor capsule or
             satellite lesions)

         11. Total tumor mass &lt; 50% liver volume

         12. Size of any individual tumor &gt;10cm in largest dimension

        Exclusion Criteria:

          1. History of acute tumor rupture presenting with hemo-peritoneum

          2. Biliary obstruction not amenable to percutaneous or endoscopic drainage

          3. Child-Pugh C cirrhosis

          4. History of hepatic encephalopathy

          5. Intractable ascites not controllable by medical therapy

          6. History of variceal bleeding within last 3 months

          7. Serum total bilirubin level &gt; 50 umol/L

          8. Serum albumin level &lt; 25g/L

          9. INR &gt; 1.7

         10. Serum creatinine level &gt; 150 mmol/L.

         11. Infiltrative tumor morphology (characterized by ill- defined tumor margin and
             amorphous configuration) or diffuse tumor morphology (characterized by large number of
             small nodules)

         12. Arterio-portal venous shunt affecting &gt;1 hepatic segment on CT

         13. Arterial-hepatic venous shunt with hepatic vein opacified in arterial phase on CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIIR, CUHK, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Wong</last_name>
    <phone>(852) 3505 3210</phone>
    <email>carmenwongsp@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pui Man Chong</last_name>
    <phone>(852) 3505 4094</phone>
    <email>siuman@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Wong</last_name>
      <phone>(852)3505 3210</phone>
      <email>carmenwongsp@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Pui Man Chong</last_name>
      <phone>(852)3505 4094</phone>
      <email>siuman@cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Simon Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

